Approved comparison material connected to this topic.
5 total recordsSource comparisons are presented without a generated winner.
To provide more context, it's helpful to see how the AOD-9604 results timeline compares to other peptides used in Metabolic & Weight Research. Each has a unique mechanism and, therefore, a different timeline f…
Body Fat % (DEXA) 1.2–2.8% reduction from baseline Not measured. Users rely on visual assessment DEXA or Bod Pod required for accuracy; calipers introduce 3–5% error margin Scale Weight Change 1.5–3.2 lbs aver…
Before evaluating your own two-week experience, it helps to understand what constitutes realistic progress versus marketing exaggeration. The table below compares expected outcomes at the 2-week mark across di…
The Garvan Institute's Phase II clinical trial. Published in 2007 and involving 300 obese participants over 12 weeks. Found zero statistically significant difference in body weight or fat mass between AOD-9604…
500 mcg daily subcutaneous No measurable DEXA change; possible 0.2–0.5 kg scale weight reduction (likely water/glycogen) 1.2–2.1 kg fat mass reduction in clinical cohorts; 3–6 mm subcutaneous fat thickness dec…